Monoclonal Antibody Therapy for COVID-19
Monoclonal antibody therapy can prevent severe illness, hospitalization and death in high-risk patients who have contracted or been exposed to COVID-19. These treatments are widely available in Florida.
- Treatment is free and vaccination status does not matter. If you are 12 years and older and are at high risk for severe illness due to COVID-19, you are eligible for this treatment.
- In clinical trials, monoclonal antibody treatment showed a 70% reduction in hospitalization and death.
- For high-risk patients who have been exposed to someone with COVID19, Regeneron can give you temporary immunity to decrease your odds of catching the infection by over 80%.
Monoclonal antibody treatments can be prescribed by health care providers to individuals 12 years of age and older who have been diagnosed with COVID-19 and who have been exposed to someone with COVID-19 and are at high risk for severe illness and hospitalization.
However, to support Governor DeSantis’ initiative, there is currently a standing order in Florida signed by Florida’s Surgeon General that allows patients to receive this treatment without a prescription or referral if administered by an eligible health care provider. Such referrals are not required at any of the state of Florida monoclonal antibody treatment sites and treatments are available at no cost to patients.
The antibodies help the immune system recognize and respond effectively to the virus. According to the treatment guidelines, they should be administered as soon as possible after diagnosis. By providing access to these treatments at these new sites, Governor DeSantis is alleviating demand on hospital resources and further making sure that Floridians have access to all potential treatments that can help them recover from COVID-19.
For more information, call the Florida Department of Health Monoclonal Antibody Treatment Support Line: 850-344-9637
Oral Antiviral Treatment for COVID-19
Paxlovid and Molnupiravir Oral Antiviral treatment sites are available in Florida.
Monoclonal antibodies help the immune system recognize and respond more effectively to the COVID-19 virus.
Monoclonal antibodies are a treatment authorized by the U.S. Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA) for use in adult and pediatric patients (12 and older) who have either been diagnosed or exposed to someone with COVID-19 and are at high risk for progression to severe illness, hospitalization, or death from COVID-19.
In clinical trials, this treatment resulted in a 70% reduction in risk for hospitalization and death, and resulted in an 82% reduction in risk for contracting COVID-19 for people who were exposed to the virus by other members of their household.
Evusheld is a preventative monoclonal antibody therapy. Eligible individuals should contact their health care provider if interested in this pre-exposure therapy.
There is not a time limit to receive other monoclonal antibody treatments, however it must be delivered prior to the occurrence of severe illness. This treatment is available to all eligible people, regardless of vaccination status.
High-risk patients should get treatment as quickly as possible after testing positive for COVID- 19. Examples of medical conditions that may pose a higher risk for severe illness and could potentially benefit from this treatment include, but are not limited to:
- Older age (65 years of age and older)
- Individuals overweight
- Chronic kidney disease
- Immunosuppressive disease or treatments
- Cardiovascular disease
- Chronic lung diseases
- Sickle cell disease
- Neurodevelopmental disorders such as cerebral palsy
- Having medical-related technological dependence such as tracheostomy or gastrostomy
There is no cost for monoclonal antibody treatment. No one will be denied services due to inability to pay for administrative cost at State of Florida sites. However, insurance can be billed if available.
At the direction of Governor DeSantis, the Florida Department of Health and Florida Division of Emergency Management are working together to deploy mobile and stationary monoclonal antibody therapy treatment sites. Click here to find a monoclonal antibody treatment site.
Individuals eligible for Evusheld should contact their health care provider if interested in this pre-exposure therapy.
As of May 2022, several treatment options are available under Emergency Use Authorization (EUA) for COVID-19:
- Options for patients not requiring hospitalization or supplemental oxygen include Paxlovid, Molnupiravir, Bebtelovimab, and remdesivir.
- If eligible, and within five days of symptom onset, Paxlovid should be considered the first treatment option.
- Bebtelovimab is currently the only monoclonal antibody treatment available for patients who test positive for COVID-19.
Eligible individuals should contact their health care provider to find out if which treatment option is appropriate for them.